Moorestown, NJ, United States of America

Norman Ruetsch

This inventor holds 1 USPTO granted patent. Top assignee: Sanofi-Aventis. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Norman Ruetsch. Retrieved from https://idiyas.com/inventor/norman-ruetsch-lg3ra6th

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Norman Ruetsch

Introduction

Norman Ruetsch is a notable inventor based in Moorsetown, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. His work has led to advancements that may impact various medical treatments.

Latest Patents

Ruetsch holds a patent for "Humanized Anti-CXCR5 Antibodies, Derivatives Thereof and Their Uses." This patent represents his innovative approach to targeting specific pathways in the immune system, which could lead to new therapies for diseases.

Career Highlights

Currently, Norman Ruetsch is associated with Sanofi-Aventis, a global biopharmaceutical company. His role at Sanofi-Aventis allows him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Some of his notable coworkers include Renata Lee and Vincent Mikol. Their combined expertise fosters a collaborative environment that enhances the potential for innovative breakthroughs in their projects.

Conclusion

Norman Ruetsch's contributions to biotechnology through his patent and work at Sanofi-Aventis highlight his role as an influential inventor in the field. His innovative spirit continues to drive advancements that may benefit medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…